David Denning

Q: What Schools Are Affiliated With David Denning

David Denning is affiliated with the following schools: University of Sheffield, University of Aberdeen, Manchester University , University of Manchester, King Saud University

David Denning's AcademicInfluence.com Rankings

David Denning

Philosophy

#2601

World Rank

#4394

Historical Rank

Logic

#666

World Rank

#1162

Historical Rank

philosophy Degrees

Download Badge

Philosophy

David Denning's Degrees

Doctorate Medicine University of Manchester

Why Is David Denning Influential?

(Suggest an Edit or Addition)

According to Wikipedia, David W. Denning is a British retired professor of infectious diseases and global health and medical mycology at the University of Manchester. He was the founding president, executive director and chief executive of Global Action For Fungal Infections , which focusses on the global impact of fungal disease.

(See a Problem?)

David Denning's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. (2008) (4348)
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. (2002) (3019)
Hidden Killers: Human Fungal Infections (2012) (2990)
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. (2008) (2526)
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. (2002) (2368)
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. (2016) (1683)
Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision (2017) (1346)
Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus (2005) (1323)
Sequencing of Aspergillus nidulans and comparative analysis with A. fumigatus and A. oryzae (2005) (1321)
Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. (2017) (1313)
Genome sequencing and analysis of Aspergillus oryzae (2005) (1134)
Echinocandin antifungal drugs (2003) (1006)
Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. (1990) (924)
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. (2002) (840)
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. (2018) (801)
The link between fungi and severe asthma: a summary of the evidence (2006) (768)
Practice Guidelines for Diseases Caused by Aspergillus (2000) (760)
Frequency and Evolution of Azole Resistance in Aspergillus fumigatus Associated with Treatment Failure (2009) (721)
Therapeutic outcome in invasive aspergillosis. (1996) (720)
Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference. (2003) (664)
Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria (2013) (629)
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. (2004) (628)
EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts: Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST)∗ (2008) (579)
Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. (2001) (569)
Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management (2015) (554)
Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. (2007) (544)
Laboratory diagnosis of invasive aspergillosis. (2005) (488)
Itraconazole resistance in Aspergillus fumigatus (1997) (487)
Tackling Human Fungal Infections (2012) (486)
Genomic Islands in the Pathogenic Filamentous Fungus Aspergillus fumigatus (2008) (483)
Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. (2003) (481)
Pulmonary aspergillosis in the acquired immunodeficiency syndrome. (1991) (472)
The clinical spectrum of pulmonary aspergillosis (2014) (470)
Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. (2012) (455)
NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. (1994) (451)
Fungi and allergic lower respiratory tract diseases. (2012) (395)
Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. (2013) (384)
How to bolster the antifungal pipeline (2015) (376)
Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma (2010) (374)
Treatment of invasive aspergillosis with itraconazole. (1989) (349)
Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. (2011) (328)
Aspergillosis. Pathogenesis, clinical manifestations, and therapy. (2002) (323)
Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. (2009) (319)
Fungal rhinosinusitis (2009) (306)
Evidence for Sexuality in the Opportunistic Fungal Pathogen Aspergillus fumigatus (2005) (300)
Therapy for fungal diseases: opportunities and priorities. (2010) (299)
High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. (2011) (288)
Prospective Multicenter International Surveillance of Azole Resistance in Aspergillus fumigatus (2015) (285)
Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. (2010) (282)
Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis (2006) (279)
Fungal allergy in asthma–state of the art and research needs (2014) (275)
International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. (2015) (270)
An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. (1998) (265)
Invasive aspergillosis in patients with AIDS. (1994) (262)
Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. (2016) (257)
Global burden of recurrent vulvovaginal candidiasis: a systematic review. (2018) (254)
Echinocandins: a new class of antifungal. (2002) (254)
Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. (2009) (247)
Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. (1991) (246)
Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis. (2008) (238)
Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. (2000) (234)
Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. (1997) (234)
Mold sensitization is common amongst patients with severe asthma requiring multiple hospital admissions (2005) (233)
The invasive and saprophytic syndromes due to Aspergillus spp. (2005) (230)
EUCAST DEFINITIVE DOCUMENT E.DEF 9.1: Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds (2008) (229)
The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus. (2013) (218)
Multi-azole resistance in Aspergillus fumigatus. (2006) (199)
Itraconazole therapy for cryptococcal meningitis and cryptococcosis. (1989) (198)
British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. (2003) (197)
Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. (1994) (196)
Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts (2003) (195)
Novel immunologic classification of aspergillosis in adult cystic fibrosis. (2013) (194)
Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome. (1991) (191)
Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole. (1991) (187)
Erratum: Allergic bronchopulmonary aspergillosis in cystic fibrosis - State of the art: Cystic Fibrosis Foundation Consensus Conference (Clinical Infectious Diseases (2003) 37:Suppl. 3 (S225-64)) (2004) (183)
Adverse reactions to voriconazole. (2004) (180)
Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. (2003) (180)
Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate. (2002) (178)
Antifungal drug resistance in Aspergillus. (2000) (176)
Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? (2006) (174)
Adverse events associated with itraconazole in 189 patients on chronic therapy. (1990) (172)
New and emerging treatments for fungal infections. (2008) (169)
Aspergillus fungemia: report of two cases and review. (1995) (165)
Threats Posed by the Fungal Kingdom to Humans, Wildlife, and Agriculture (2020) (163)
High prevalence of antifungal resistance in Candida spp. from patients with AIDS. (1994) (159)
Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing. EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. (2009) (158)
Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. (1992) (156)
Chronic forms of pulmonary aspergillosis. (2001) (154)
Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma (2009) (153)
Post-operative aspergillosis. (2006) (151)
Mannose-binding lectin gene polymorphisms as a susceptibility factor for chronic necrotizing pulmonary aspergillosis. (2001) (149)
In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. (1992) (146)
Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. (2008) (143)
Global burden of chronic pulmonary aspergillosis complicating sarcoidosis (2012) (139)
Therapeutic drug monitoring for triazoles (2008) (138)
Molecular Mechanisms of Primary Resistance to Flucytosine in Candida albicans (2004) (136)
British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases. (2015) (135)
Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). (2003) (134)
Restriction endonuclease analysis of total cellular DNA of Aspergillus fumigatus isolates of geographically and epidemiologically diverse origin. (1990) (134)
Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. (1995) (134)
The European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) EUCAST Technical Note on fluconazole. (2009) (130)
Mycoses in AIDS Patients (2011) (128)
Echinocandins and pneumocandins--a new antifungal class with a novel mode of action. (1997) (128)
Voriconazole and Posaconazole Improve Asthma Severity in Allergic Bronchopulmonary Aspergillosis and Severe Asthma with Fungal Sensitization (2012) (126)
Endemic mycoses: a treatment update. (1999) (126)
Fluconazole‐resistant candidosis in an HIV cohort (1994) (126)
Acute myelopathy associated with primary infection with human immunodeficiency virus. (1987) (126)
Invasive infection due to penicillium species other than P. marneffei. (2002) (124)
Cyclosporine and itraconazole interaction in heart and lung transplant recipients. (1990) (122)
Itraconazole therapy for chronic coccidioidal meningitis. (1990) (121)
Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. (1991) (121)
Azole Cross-Resistance in Aspergillus fumigatus (2002) (116)
Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. (2006) (115)
Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. (2010) (115)
Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. (2009) (115)
Administering amphotericin B--a practical approach. (1994) (115)
Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus (1997) (114)
Pulmonary cryptococcosis: A review of pathobiology and clinical aspects. (2018) (112)
Comparison of six Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis (CPA). (2016) (111)
Efficacy of LY303366 against Amphotericin B-Susceptible and -Resistant Aspergillus fumigatus in a Murine Model of Invasive Aspergillosis (1998) (110)
Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis (2009) (108)
The global incidence and diagnosis of fungal keratitis. (2020) (108)
Global access to antifungal therapy and its variable cost. (2016) (107)
Histoplasmosis in Africa: An emerging or a neglected disease? (2018) (107)
In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp (1997) (106)
Cryptic Species and Azole Resistance in the Aspergillus niger Complex (2011) (105)
Multilocus Sequence Typing of Candidaglabrata Reveals Geographically EnrichedClades (2003) (104)
Invasive yeast infections other than Candida spp. in acute leukaemia. (1999) (103)
Results of surgery for chronic pulmonary Aspergillosis, optimal antifungal therapy and proposed high risk factors for recurrence - a National Centre’s experience (2013) (101)
Invasive aspergillosis. (1998) (100)
Sequencing of mitochondrial genomes of nine Aspergillus and Penicillium species identifies mobile introns and accessory genes as main sources of genome size variability (2012) (100)
Multicenter, Prospective Clinical Evaluation of Respiratory Samples from Subjects at Risk for Pneumocystis jirovecii Infection by Use of a Commercial Real-Time PCR Assay (2011) (99)
Re-drawing the Maps for Endemic Mycoses (2020) (99)
Predictors of mortality in chronic pulmonary aspergillosis (2017) (99)
Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis (2020) (99)
CADRE: the Central Aspergillus Data REpository (2004) (97)
Estimation of the Burden of Chronic and Allergic Pulmonary Aspergillosis in India (2014) (96)
Sequencing the Aspergillus fumigatus genome. (2002) (96)
Transplacental transfer of aflatoxin in humans. (1990) (96)
Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. (2005) (96)
Candida tropicalis in human disease (2010) (95)
Distinct alleles of mannose-binding lectin (MBL) and surfactant proteins A (SP-A) in patients with chronic cavitary pulmonary aspergillosis and allergic bronchopulmonary aspergillosis (2007) (95)
Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation (1997) (94)
Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options (2014) (94)
A Cautionary Tale: Lack of Consistency in Allele Sizes between Two Laboratories for a Published Multilocus Microsatellite Typing System (2006) (94)
Azole resistance in Aspergillus: a growing public health menace. (2011) (93)
What can comparative genomics tell us about species concepts in the genus Aspergillus? (2007) (93)
Multi-Country Estimate of Different Manifestations of Aspergillosis in Cystic Fibrosis (2014) (93)
Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500 000 by 2020 to be realized (2016) (92)
The burden of serious human fungal infections in Brazil (2016) (91)
Treatment of invasive aspergillosis. (1994) (91)
In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. (2006) (89)
Diagnosis and management of invasive aspergillosis. (1996) (89)
Fluconazole resistance in Candida in patients with AIDS--a therapeutic approach. (1993) (89)
Molecular typing by random amplification of polymorphic DNA and M13 southern hybridization of related paired isolates of Aspergillus fumigatus (1996) (89)
Interrogation of Related Clinical Pan-Azole-Resistant Aspergillus fumigatus Strains: G138C, Y431C, and G434C Single Nucleotide Polymorphisms in cyp51A, Upregulation of cyp51A, and Integration and Activation of Transposon Atf1 in the cyp51A Promoter (2011) (88)
Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation (2019) (87)
In Vitro Activity of the Echinocandin Antifungal Agent LY303,366 in Comparison with Itraconazole and Amphotericin B against Aspergillus spp (1998) (87)
Molecular Detection and Identification of Zygomycetes Species from Paraffin-Embedded Tissues in a Murine Model of Disseminated Zygomycosis: a Collaborative European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) Evaluation (2010) (87)
Pharmacokinetics and Pharmacodynamics of a Novel Triazole, Isavuconazole: Mathematical Modeling, Importance of Tissue Concentrations, and Impact of Immune Status on Antifungal Effect (2009) (86)
EUCAST technical note on fluconazole. (2008) (84)
Performance of two Aspergillus IgG EIA assays compared with the precipitin test in chronic and allergic aspergillosis. (2013) (84)
Evidence of multiple extracellular phospholipase activities of Aspergillus fumigatus (1996) (84)
Molecular genetics in Aspergillus fumigatus. (2000) (81)
Comparative genomics of fungal allergens and epitopes shows widespread distribution of closely related allergen and epitope orthologues (2006) (81)
Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis. (2010) (80)
Multilocus Sequence Typing of Candida glabrata Reveals Geographically Enriched Clades (2003) (80)
Antibody testing in aspergillosis--quo vadis? (2015) (79)
Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. (2006) (79)
The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. (2006) (78)
Estimating the burden of invasive and serious fungal disease in the United Kingdom. (2017) (77)
Cytokine profiling of pulmonary aspergillosis (2006) (76)
Environmental fungicides and triazole resistance in Aspergillus. (2014) (76)
Inactivation of Transcription Factor Gene ACE2 in the Fungal Pathogen Candida glabrata Results in Hypervirulence (2004) (75)
In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. (1998) (75)
Allergic bronchopulmonary aspergillosis and related allergic syndromes. (2011) (75)
Pulmonary and sinus fungal diseases in non-immunocompromised patients. (2017) (75)
Interlaboratory Evaluation of Hematocytometer Method of Inoculum Preparation for Testing Antifungal Susceptibilities of Filamentous Fungi (2003) (74)
IgE-mediated immune responses and airway detection of Aspergillus and Candida in adult cystic fibrosis. (2013) (74)
Excess mortality, length of stay and cost attributable to candidaemia. (2009) (73)
Corticosteroid treatment is associated with increased filamentous fungal burden in allergic fungal disease (2017) (73)
Risk assessment on the impact of environmental usage of triazoles on the development and spread of resistance to medical triazoles in Aspergillus species. Stockholm: ECDC; 2013 (2013) (73)
Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations. (1990) (73)
Resistance to fluconazole in Candida albicans from AIDS patients correlated with reduced intracellular accumulation of drug. (1995) (72)
Validation of an Assay for Voriconazole in Serum Samples Using Liquid Chromatography-Tandem Mass Spectrometry (2004) (72)
Aspergillus bronchitis without significant immunocompromise (2012) (72)
Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis (1991) (71)
Commentary: unusual manifestations of aspergillosis. (1995) (71)
Case Definition of Chronic Pulmonary Aspergillosis in Resource-Constrained Settings (2018) (71)
Volume dependency for culture of fungi from respiratory secretions and increased sensitivity of Aspergillus quantitative PCR (2014) (71)
Fortnightly Review: Fungal nail disease: a guide to good practice (report of a Working Group of the British Society for Medical Mycology) (1995) (71)
The effects of antifungal therapy on severe asthma with fungal sensitization and allergic bronchopulmonary aspergillosis (2009) (70)
High-level expression of cyp51B in azole-resistant clinical Aspergillus fumigatus isolates. (2013) (69)
Performance of cryptococcus antigen latex agglutination kits on serum and cerebrospinal fluid specimens of AIDS patients before and after pronase treatment (1991) (68)
Erratum: NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis (American Journal of Medicine (August 1994) 97 (135-144)) (1994) (68)
Intravenous antibiotics reduce the presence of Aspergillus in adult cystic fibrosis sputum (2013) (68)
Comparison of In Vitro Activity of Liposomal Nystatin againstAspergillus Species with Those of Nystatin, Amphotericin B (AB) Deoxycholate, AB Colloidal Dispersion, Liposomal AB, AB Lipid Complex, and Itraconazole (1999) (68)
Candida glabrata STE12 is required for wild‐type levels of virulence and nitrogen starvation induced filamentation (2003) (68)
An algorithmic approach to aspergillus sinusitis (1994) (65)
Chronic mucocutaneous candidiasis and oesophageal cancer. (2008) (64)
Evidence for recombination in Candida glabrata. (2005) (64)
Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: a longitudinal analysis. (2013) (64)
Burden of serious fungal infections in Spain. (2015) (63)
Delivering on Antimicrobial Resistance Agenda Not Possible without Improving Fungal Diagnostic Capabilities (2017) (63)
Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance (1996) (63)
In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. (1998) (63)
A study on Aspergillus species in houses of asthmatic patients from Sari City, Iran and a brief review of the health effects of exposure to indoor Aspergillus (2010) (62)
Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. (2001) (62)
Oxygen requirements of Aspergillus species. (1994) (61)
Antifungal susceptibility testing in Aspergillus spp. according to EUCAST methodology. (2006) (61)
Insight into the genome of Aspergillus fumigatus: analysis of a 922 kb region encompassing the nitrate assimilation gene cluster. (2004) (61)
Correlation between in vitro growth rate and in vivo virulence in Aspergillus fumigatus. (2005) (60)
Statistical Analyses of Correlation between Fluconazole MICs for Candida spp. Assessed by Standard Methods Set Forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2) (2006) (60)
A Review of Onychomycosis Due to Aspergillus Species (2017) (60)
Impaired dendritic cell maturation and cytokine production in patients with chronic mucocutanous candidiasis with or without APECED (2008) (59)
In Vitro Activity of the New Triazole BMS-207147 againstAspergillus Species in Comparison with Itraconazole and Amphotericin B (2000) (59)
Pathophysiological aspects of Aspergillus colonization in disease. (2018) (59)
Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the Intergroupe Français du Myélome. (2000) (58)
Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards (1994) (58)
Flucytosine therapeutic monitoring: 15 years experience from the UK. (2007) (58)
In Vitro Activities of Terbinafine againstAspergillus Species in Comparison with Those of Itraconazole and Amphotericin B (2001) (57)
Aspergillus nodules; another presentation of Chronic Pulmonary Aspergillosis (2016) (57)
An estimation of burden of serious fungal infections in France. (2016) (57)
Too Many Mouldy Joints – Marijuana and Chronic Pulmonary Aspergillosis (2011) (57)
Can we prevent azole resistance in fungi? (1995) (56)
CADRE: the Central Aspergillus Data REpository. (2004) (56)
Chronic pulmonary aspergillosis as a cause of smear-negative TB and/or TB treatment failure in Nigerians. (2017) (56)
Burden of serious fungal infection in Nigeria. (2014) (55)
Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp (1997) (55)
Aspergillus DNA contamination in blood collection tubes. (2010) (54)
Pulmonary aspergillosis: an alternative diagnosis to lung cancer after positive [18F]FDG positron emission tomography (2011) (54)
Genomic analysis of allergen genes in Aspergillus spp: the relevance of genomics to everyday research. (2007) (54)
Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida. (2004) (54)
Amphotericin B resistance testing of Candida spp.: a comparison of methods. (1997) (53)
Dose Range Evaluation of Liposomal Nystatin and Comparisons with Amphotericin B and Amphotericin B Lipid Complex in Temporarily Neutropenic Mice Infected with an Isolate of Aspergillus fumigatus with Reduced Susceptibility to Amphotericin B (1999) (53)
Reduction in oropharyngeal candidiasis following introduction of protease inhibitors. (1998) (53)
A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease. (2001) (52)
Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. (2019) (52)
Treatment of coccidioidal meningitis with fluconazole. (1990) (52)
Comparison of two fluorescent whiteners, Calcofluor and Blankophor, for the detection of fungal elements in clinical specimens in the diagnostic laboratory. (2006) (52)
Homogenisation of cystic fibrosis sputum by sonication--an essential step for Aspergillus PCR. (2011) (51)
Azole Antifungal Resistance Today: Focus on Aspergillus (2011) (51)
Itraconazole in opportunistic mycoses: cryptococcosis and aspergillosis. (1990) (51)
Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis (2018) (50)
Improvement of fungal disease identification and management: combined health systems and public health approaches. (2017) (50)
Prevalence of chronic pulmonary aspergillosis in patients with tuberculosis from Iran (2015) (50)
Peripheral neuropathy in patients on long-term triazole antifungal therapy. (2011) (49)
Emergence of Echinocandin Resistance Due to a Point Mutation in the fks1 Gene of Aspergillus fumigatus in a Patient with Chronic Pulmonary Aspergillosis (2017) (49)
The ambitious ‘95–95 by 2025’ roadmap for the diagnosis and management of fungal diseases (2015) (49)
The Management of Chronic Pulmonary Aspergillosis: The UK National Aspergillosis Centre Approach (2017) (48)
Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis (1995) (48)
Genetic variability of innate immunity impacts human susceptibility to fungal diseases. (2010) (48)
Corrigendum: Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus (2006) (48)
Voriconazole plasma monitoring (2008) (47)
Generic substitution of itraconazole resulting in sub-therapeutic levels and resistance. (2007) (47)
Voriconazole resistance in Aspergillus fumigatus: should we be concerned? (2013) (46)
Antifungal prophylaxis during neutropenia or allogeneic bone marrow transplantation: what is the state of the art? Ad HOC Working Group. (1992) (46)
The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis. (2022) (46)
Whole genome comparison of the A. fumigatus family. (2006) (46)
Genomics of Aspergillus fumigatus. (2005) (46)
Voriconazole‐induced photosensitivity: photobiological assessment of a case series of 12 patients (2013) (45)
Management of deepCandida infection in surgical and intensive care unit patients (1994) (45)
Histoplasma capsulatum antigen detection tests as an essential diagnostic tool for patients with advanced HIV disease in low and middle income countries: A systematic review of diagnostic accuracy studies (2018) (45)
Anti-Aspergillus Activities of the Respiratory Epithelium in Health and Disease (2018) (45)
Occurrence of azole-resistant species of Aspergillus in the UK environment. (2014) (44)
Current trends in the detection of antigenaemia, metabolites and cell wall markers for the diagnosis and therapeutic monitoring of fungal infections. (1998) (44)
Efficacy and safety of nebulised amphotericin B (NAB) in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA) (2015) (44)
Estimated burden of fungal infections in Germany (2015) (44)
Global burden of chronic pulmonary aspergillosis as a sequel to tuberculosis. (2011) (44)
Skull base osteitis following fungal sinusitis (1998) (43)
Azole resistance in Candida. (1997) (43)
Control of Candida auris in healthcare institutions: Outcome of an International Society for Antimicrobial Chemotherapy expert meeting (2019) (43)
Treatment of fungal infection in AIDS. (1996) (43)
Restriction endonuclease analysis of human and bovine group B streptococci for epidemiologic study (1989) (43)
Serious fungal infections in Pakistan (2017) (43)
Calling upon all public health mycologists (2017) (42)
High-volume culture and quantitative real-rime PCR for the detection of Aspergillus in sputum. (2019) (42)
Lack of vessel wall elastolysis in human invasive pulmonary aspergillosis (1992) (42)
Cryptococcal meningitis: A neglected NTD? (2017) (42)
Commentaries: Name Changes in Medically Important Fungi and Their Implications for Clinical Practice (2014) (42)
In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis. (2002) (42)
The one health problem of azole resistance in Aspergillus fumigatus: current insights and future research agenda (2020) (42)
Successful treatment of sinusitis caused by Cunninghamella bertholletiae. (1994) (42)
In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. (2001) (41)
Species differentiation by internally transcribed spacer PCR and HhaI digestion of fluconazole-resistant Candida krusei, Candida inconspicua, and Candida norvegensis strains (1997) (41)
Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort (2010) (41)
Comparison of extracellular phospholipase activities in clinical and environmental Aspergillus fumigatus isolates. (2004) (40)
The global impact of Aspergillus infection on COPD (2020) (40)
Major variations in Aspergillus fumigatus arising within aspergillomas in chronic pulmonary aspergillosis (2013) (40)
Burden of serious fungal infections in Nepal (2015) (40)
What the Aspergillus genomes have told us. (2005) (39)
Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus. (2010) (39)
Republished: The clinical spectrum of pulmonary aspergillosis (2014) (39)
Invasive aspergillosis: current and future challenges in diagnosis and therapy. (2004) (39)
Erratum: The European Committee on antimicrobial susceptibility testing - Subcommittee on antifungal susceptibility testing (EUCAST-AFST)*. EUCAST technical note on fluconazole (Clinical Microbiology and Infection (2008) vol. 14(2) (193-195)) (2009) (39)
Aspergillosis in "nonimmunocompromised" critically ill patients. (2004) (39)
Efficacy of oral saperconazole in systemic murine aspergillosis. (1995) (39)
Burden of fungal asthma in Africa: A systematic review and meta-analysis (2019) (39)
Early diagnosis of invasive aspergillosis (2000) (38)
Cryptococcal disease and the burden of other fungal diseases in Uganda; Where are the knowledge gaps and how can we fill them? (2015) (38)
US experience with itraconazole in Aspergillus, Cryptococcus and Histoplasma infections in the immunocompromised host. (1992) (38)
Identification of novel genes conferring altered azole susceptibility in Aspergillus fumigatus. (2012) (38)
Effect of Neutropenia and Treatment Delay on the Response to Antifungal Agents in Experimental Disseminated Candidiasis (2006) (38)
The burden of serious fungal diseases in Russia (2015) (38)
Standards of care for patients with invasive fungal infections within the United Kingdom: a national audit. (2009) (37)
Burden of Fungal Infections in Colombia (2018) (37)
Neuralgic amyotrophy due to parvovirus infection. (1987) (37)
Fortnightly Review: Management of genital candidiasis (1995) (37)
Burden of serious fungal infections in Mexico (2015) (36)
Molecular typing of Aspergillus species. (1995) (36)
Mannose‐binding lectin genotype and serum levels in patients with chronic and allergic pulmonary aspergillosis (2012) (36)
Clinical implications of interferon‐γ genetic and epigenetic variants (2014) (36)
Burden of serious fungal infections in Tanzania (2015) (35)
Lung colonization by Aspergillus fumigatus is controlled by ZNF77 (2018) (35)
Serious fungal infections in Canada (2017) (35)
Validity and reliability of the St. George's Respiratory Questionnaire in assessing health status in patients with chronic pulmonary aspergillosis. (2013) (35)
Endocarditis due to Trichosporon beigelii: in vitro susceptibility of isolates and review. (1991) (35)
The global distribution of actinomycetoma and eumycetoma (2020) (35)
Frequency, diagnosis and management of fungal respiratory infections (2013) (35)
Burden of fungal infections in Qatar (2015) (35)
Uncommon invasive mycoses in AIDS. (1995) (35)
The neurological features of acute HIV infection. (1988) (35)
The Diagnosis of Fungal Neglected Tropical Diseases (Fungal NTDs) and the Role of Investigation and Laboratory Tests: An Expert Consensus Report (2019) (34)
Scedosporium prolificans, a multi-resistant fungus, from a U.K. AIDS patient. (1995) (34)
Comparison of Guizotia abyssinica seed extract (birdseed) agar with conventional media for selective identification of Cryptococcus neoformans in patients with acquired immunodeficiency syndrome (1990) (34)
Aflatoxin and human disease. (1987) (34)
Tuberculosis/cryptococcosis co-infection in China between 1965 and 2016 (2017) (34)
Derivation of an In Vivo Drug Exposure Breakpoint for Flucytosine against Candida albicans and Impact of the MIC, Growth Rate, and Resistance Genotype on the Antifungal Effect (2006) (34)
Serious fungal infections in Egypt (2017) (34)
Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis. (2005) (34)
In vitro activity of D0870 compared with those of other azoles against fluconazole-resistant Candida spp (1995) (34)
DNA fingerprinting of Aspergillus fumigatus isolates from patients with aspergilloma. (1991) (34)
Invasive aspergillosis in immunocompromised patients (1994) (33)
PERIPHERAL SYMMETRICAL GANGRENE SUCCESSFULLY TREATED WITH EPOPROSTENOL AND TISSUE PLASMINOGEN ACTIVATOR (1986) (33)
Oral Itraconazole Therapy of Cryptococcal Meningitis and Cryptococcosis in Patients with AIDS (1990) (33)
AIDS-related mycoses: the way forward. (2014) (33)
Antifungal Susceptibility Testing of Fluconazole by Flow Cytometry Correlates with Clinical Outcome (2001) (32)
The case for paracoccidioidomycosis to be accepted as a neglected tropical (fungal) disease (2019) (32)
A prominent role for the IL1 pathway and IL15 in susceptibility to chronic cavitary pulmonary aspergillosis. (2014) (32)
Aspergillosis and the role of mucins in cystic fibrosis (2016) (32)
DNA typing of epidemiologically-related isolates of Aspergillus fumigatus (1995) (32)
Pulmonary aspergillosis in AIDS [1] (1991) (32)
Aspergillosis: diagnosis and treatment. (1996) (32)
Diagnostic and Therapeutic Strategies for Invasive Aspergillosis (1997) (31)
Neisseria lactamica meningitis following skull trauma. (1991) (31)
Aspergillus fumigatus catalases: cloning of an Aspergillus nidulans catalase B homologue and evidence for at least three catalases. (1999) (31)
Candida inconspicua, a fluconazole-resistant pathogen in patients infected with human immunodeficiency virus. (1997) (31)
An investigation of antifungal stewardship programmes in England (2017) (31)
HIV-Associated Cryptococcal Disease in Resource-Limited Settings: A Case for “Prevention Is Better Than Cure”? (2017) (30)
Mitochondrial Complex I Is a Global Regulator of Secondary Metabolism, Virulence and Azole Sensitivity in Fungi (2016) (30)
Inhibition and interaction of cytochrome P450 of Candida krusei with azole antifungal drugs. (1997) (30)
Burden of fungal disease in Ireland. (2015) (30)
Receiver operating characteristic curve analysis of four Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis. (2018) (30)
The Performance of Real-Time PCR, Galactomannan, and Fungal Culture in the Diagnosis of Invasive Aspergillosis in Ventilated Patients with Chronic Obstructive Pulmonary Disease (COPD) (2012) (29)
Evaluation of LDBio Aspergillus ICT Lateral Flow Assay for IgG and IgM Antibody Detection in Chronic Pulmonary Aspergillosis (2019) (29)
Detection of Aspergillus in lung and other tissue samples using the MycAssay Aspergillus real-time PCR kit. (2011) (29)
Advances against aspergillosis. (2003) (29)
Burden of fungal infections in Algeria (2017) (29)
Reduced expression of TLR3, TLR10 and TREM1 by human macrophages in Chronic cavitary pulmonary aspergillosis, and novel associations of VEGFA, DENND1B and PLAT. (2014) (29)
D-mannitol in cerebrospinal fluid of patients with AIDS and cryptococcal meningitis (1996) (28)
Burden of serious fungal infections in Guatemala (2017) (28)
Burden of fungal infections in Senegal (2015) (28)
Serious fungal infections in Portugal (2017) (28)
An estimate of the burden of serious fungal diseases in Greece (2016) (28)
Endogenous Candida endophthalmitis and osteomyelitis associated with CARD9 deficiency (2016) (28)
Effect of involved Aspergillus species on galactomannan in bronchoalveolar lavage of patients with invasive aspergillosis (2017) (27)
Future Research Priorities in Fungal Resistance (2017) (27)
Endophthalmitis in a patient with disseminated cryptococcosis and AIDS who was treated with itraconazole. (1991) (27)
A global call for talaromycosis to be recognised as a neglected tropical disease. (2021) (27)
The Burden of Serious Fungal Infections in Cameroon (2018) (27)
Essential in vitro diagnostics for advanced HIV and serious fungal diseases: international experts’ consensus recommendations (2019) (27)
Genetic susceptibility to severe asthma with fungal sensitization (2017) (27)
Genetic susceptibility to allergic bronchopulmonary aspergillosis in asthma: a genetic association study (2016) (27)
HIV ANTIGENAEMIA IN ACUTE HIV INFECTION (1987) (26)
Estimated burden of fungal infections in Kenya. (2016) (26)
Aspergilli — significance as pathogens (1993) (26)
Unilateral wheeze caused by pseudomembranous aspergillus tracheobronchitis in the immunocompromised patient. (1993) (26)
Recovery from serious fungal infections should be realisable for everyone. (2017) (26)
Atypical eumycetoma caused by Phialophora parasitica successfully treated with itraconazole and flucytosine (1997) (26)
The challenge of invasive aspergillosis: Increasing numbers in diverse patient groups (1997) (26)
Mapping histoplasmosis in South East Asia – implications for diagnosis in AIDS (2018) (26)
Comparison of D0870, a new triazole antifungal agent, to fluconazole for inhibition of Candida albicans cytochrome P-450 by using in vitro assays (1996) (26)
Karyotyping of fluconazole-resistant yeasts with phenotype reported as Candida krusei or Candida inconspicua. (1996) (25)
Stress-Induced Changes in the Lipid Microenvironment of β-(1,3)-d-Glucan Synthase Cause Clinically Important Echinocandin Resistance in Aspergillus fumigatus (2019) (25)
Randomised comparison of voriconazole and amphotericin B in primary therapy of invasive aspergillosis. (2002) (25)
Aspergillus arthritis: analysis of clinical manifestations, diagnosis, and treatment of 31 reported cases (2016) (25)
The Diagnostic Laboratory Hub: A New Health Care System Reveals the Incidence and Mortality of Tuberculosis, Histoplasmosis, and Cryptococcosis of PWH in Guatemala (2019) (25)
SUCCESSFUL TREATMENT OF ASPERGILLUS BRAIN ABSCESS IN A CHILD WITH ACUTE LYMPHOBLASTIC LEUKEMIA (2000) (25)
Elevated Aspergillus-specific antibody levels among HIV infected Ugandans with pulmonary tuberculosis (2017) (24)
Failure of single dose amoxycillin as prophylaxis against endocarditis (1984) (24)
Serious fungal infections in Thailand (2017) (24)
The Burden of Fungal Infections in Ethiopia (2019) (24)
Impact of liposomal amphotericin B therapy on chronic pulmonary aspergillosis. (2016) (24)
Development of chronic pulmonary aspergillosis in adult asthmatics with ABPA. (2015) (24)
Bone and joint infections caused by mucormycetes: A challenging osteoarticular mycosis of the twenty‐first century (2017) (24)
Getting Histoplasmosis on the Map of International Recommendations for Patients with Advanced HIV Disease (2019) (24)
Acute pulmonary aspergillosis in immunocompetent subjects after exposure to bark chippings (2006) (24)
Aflatoxin and Ochratoxin Production by Aspergillus Species Under Ex Vivo Conditions (2009) (23)
Development and Evaluation of a Calibrator Material for Nucleic Acid-Based Assays for Diagnosing Aspergillosis (2013) (23)
Cryptococcal Antigenemia in Nigerian Patients With Advanced Human Immunodeficiency Virus: Influence of Antiretroviral Therapy Adherence (2016) (23)
Estimation of the Burden of Serious Human Fungal Infections in Malaysia (2018) (23)
Therapy of deep fungal infection in haematological malignancy. Working Party of the British Society for Antimicrobial Chemotherapy. (1997) (23)
Aflatoxin and outcome from acute lower respiratory infection in children in The Philippines. (1995) (23)
Cryptococcal meningitis in the immunocompromised host: intracranial hypertension and other complications (2004) (23)
What is the importance of classifying Aspergillus disease in cystic fibrosis patients? (2014) (23)
Comparative performance of Aspergillus galactomannan ELISA and PCR in sputum from patients with ABPA and CPA. (2017) (23)
Invasive pulmonary aspergillosis transformed into fatal mucous impaction by immune reconstitution in an AIDS patient (2005) (23)
Burden of Serious Fungal Infections in Argentina (2018) (22)
The global burden of chromoblastomycosis (2021) (22)
Name Changes in Medically Important Fungi and Their Implications for Clinical Practice Medical Fungi (2015) (22)
Siemens Immulite Aspergillus-specific IgG assay for chronic pulmonary aspergillosis diagnosis (2019) (22)
Aspergillus Genomes and the Aspergillus Cloud (2008) (22)
The burden of fungal disease in Denmark (2015) (21)
Azole resistance inCandida (1997) (21)
Estimated Burden of Serious Fungal Infections in Mozambique (2018) (21)
Chronic Pulmonary Aspergillosis: Notes for a Clinician in a Resource-Limited Setting Where There Is No Mycologist (2020) (21)
Isolation of Candida norvegensis from clinical specimens: four case reports. (1996) (21)
Risk-Based Estimate of Human Fungal Disease Burden, China (2020) (21)
Cutaneous Mycobacterium thermoresistibile infection in a heart transplant recipient. (1989) (21)
Burden of serious fungal infections in the Netherlands (2020) (21)
Innate and Adaptive Immune Defects in Chronic Pulmonary Aspergillosis (2017) (21)
Using aCGH to study intraspecific genetic variability in two pathogenic molds, Aspergillus fumigatus and Aspergillus flavus. (2009) (21)
Estimated Burden of Serious Fungal Infections in Ghana (2019) (21)
Infant with two relapses of group B streptococcal sepsis documented by DNA restriction enzyme analysis. (1988) (20)
Aspergillus fumigatus Bronchopneumonia in a Hellenic Shepherd Dog. (2011) (20)
Burden of serious fungal infections in the Dominican Republic. (2016) (20)
In-vitro activity of the new triazole D0870 compared with amphotericin B and itraconazole against Aspergillus spp. (1993) (20)
Tremor: a newly described adverse event with long-term itraconazole therapy (2010) (20)
Isolation, identification and susceptibility of Pyrenochaeta romeroi in a case of eumycetoma of the foot in the UK. (2009) (20)
Burden of fungal infections in Iran. (2018) (20)
Analysis of definitions used in clinical research on invasive fungal infections Consensus proposal for new, standardized definitions (1999) (20)
Burden of serious fungal infections in Belgium (2015) (20)
Burden of serious fungal infections in Bangladesh (2017) (20)
Burden of Serious Fungal Infections in Jordan (2018) (20)
Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis. (2005) (19)
An aspergilloma caused by Aspergillus flavus. (2008) (19)
Improved Detection of Invasive Pulmonary Aspergillosis Arising during Leukemia Treatment Using a Panel of Host Response Proteins and Fungal Antigens (2015) (19)
The estimated burden of fungal disease in South Africa (2019) (19)
Burden of serious fungal infections in the Czech Republic (2015) (19)
Relative reactivity of Aspergillus allergens used in serological tests. (2006) (19)
Serious fungal infections in the Philippines (2017) (19)
High incidence of antifungal drug resistance in Candida tropicalis. (1996) (19)
Microbial yield from physiotherapy assisted sputum production in respiratory outpatients (2016) (18)
Aspergillus wound infection following laparostomy. (1996) (18)
The Burden of Fungal Diseases in Romania (2018) (18)
Quantitative preservation of viability of Aspergillus fumigatus. (1992) (18)
Frequency of Pneumocystis jirovecii in sputum from HIV and TB patients in Namibia. (2014) (18)
Diagnosis of Invasive Fungal Infections - Current Limitations of Classical and New Diagnostic Methods (2005) (18)
Risk factors associated with respiratory infectious disease-related presenteeism: a rapid review (2021) (18)
An ELISA method for the rapid and simple determination of aflatoxin in human serum. (1988) (18)
Empiric amphotericin B therapy: the need for a reappraisal. (1993) (18)
Rapid genotyping ofEscherichia coli O157 isolates by random amplification of polymorphic DNA (1996) (18)
Issues in the management of invasive aspergillosis. (1995) (18)
Serious fungal infections in Chile (2017) (18)
Optimization of the Dosage of Flucytosine in Combination with Amphotericin B for Disseminated Candidiasis: a Pharmacodynamic Rationale for Reduced Dosing (2007) (18)
Mycetoma in Uganda: A neglected tropical disease (2020) (18)
Measurement of aflatoxin in Nigerian sera by enzyme-linked immunosorbent assay. (1988) (17)
Comparative performance of the laboratory assays used by a diagnostic laboratory hub for opportunistic infections in people living with HIV. (2020) (17)
Burden of serious fungal infections in Ukraine (2015) (17)
World Health Organization Ranking of Antimicrobials According to Their Importance in Human Medicine. (2017) (17)
New drugs for systemic fungal infections. (1989) (17)
Estimated burden of serious human fungal diseases in Turkey (2018) (17)
Allergic bronchopulmonary mycosis due to Alternaria: Case report and review. (2012) (17)
Estimated Burden of Serious Fungal Infections in Malawi (2018) (17)
Long-Term Stability at −20°C of Aspergillus Galactomannan in Serum and Bronchoalveolar Lavage Specimens (2014) (17)
Electrophilic, Activation-Free Fluorogenic Reagent for Labeling Bioactive Amines. (2016) (17)
Burden of serious fungal infections in Trinidad and Tobago (2015) (17)
Elevated levels of the neutrophil chemoattractant pro-platelet basic protein in macrophages from individuals with chronic and allergic aspergillosis. (2015) (17)
Bridging the knowledge gap on mycoses in Africa: Setting up a Pan‐African Mycology Working Group (2019) (16)
Comparison of 2 studies of treatment of invasive aspergillosis. (2007) (16)
A Rapid Screening Program for Histoplasmosis, Tuberculosis, and Cryptococcosis Reduces Mortality in HIV Patients from Guatemala (2021) (16)
Molecular Typing of Aspergillus terreus by Random Amplification of Polymorphic DNA (1999) (16)
Diagnosis and Management of Pneumocystis Pneumonia in Resource-poor Settings (2018) (16)
Influenza-like episodes in HIV-positive patients: the role of viral and 'atypical' infections. (1998) (16)
Control of invasive pulmonary aspergillosis with oral itraconazole in a bone marrow transplant patient. (1992) (16)
Control of Candida auris in healthcare institutions. Outcome of an ISAC expert meeting. (2019) (16)
Chronic Pulmonary Histoplasmosis—A Scoping Literature Review (2020) (16)
The role of antifungals in the management of patients with severe asthma (2020) (15)
Estimated Burden of Fungal Infections in Namibia (2019) (15)
Epidemiology of invasive aspergillosis in European cancer centres (1993) (15)
Aspergillus and aspergillosis-Progress on many fronts. (2006) (15)
Renal aspergilloma--a case illustrating the problems of medical therapy. (1987) (15)
Evaluation of the LDBio Aspergillus ICT lateral flow assay for serodiagnosis of allergic bronchopulmonary aspergillosis (2020) (15)
Response to pneumococcal polysaccharide vaccination in patients with chronic and allergic aspergillosis. (2015) (15)
Serious fungal infections in Peru (2017) (15)
Burden of Severe Fungal Infections in Burkina Faso (2018) (15)
Myocarditis complicating ethylene glycol poisoning in the absence of neurological features. (1988) (14)
The relationship between 'normal' fluid retention in women and idiopathic oedema. (1990) (14)
Inducible Cell Fusion Permits Use of Competitive Fitness Profiling in the Human Pathogenic Fungus Aspergillus fumigatus (2018) (14)
Prior subclinical histoplasmosis revealed in Nigeria using histoplasmin skin testing (2018) (14)
Characterisation of fatigue and its substantial impact on health status in a large cohort of patients with chronic pulmonary aspergillosis (CPA). (2016) (14)
Mutations in EEA1 are associated with allergic bronchopulmonary aspergillosis and affect phagocytosis of Aspergillus fumigatus by human macrophages (2018) (14)
Burden of serious fungal diseases in Hungary (2015) (14)
Estimating the Burden of Fungal Diseases in Israel. (2015) (14)
Burden of serious fungal infections in the (2016) (14)
Chronic fibrosing pulmonary aspergillosis: a cause of ‘destroyed lung’ syndrome (2017) (14)
Temperature-dependent expression of elastase in Aspergillus species (1993) (14)
Multifocal pulmonary aspergillomas: case series and review (2012) (14)
Prospective study of the serum Aspergillus-specific IgG, IgA and IgM assays for chronic pulmonary aspergillosis diagnosis (2019) (13)
One Health aspects & priority roadmap for fungal diseases : A mini-review (2021) (13)
Diagnosis of IPA in HIV: the role of the chest X-ray and radiologist (2004) (13)
Variation in morphotype, karyotype and DNA type of fluconazole resistant Candida albicans from an AIDS patient. (1998) (13)
Pulmonary Aspergillosis in a Patient with Chronic Granulomatous Disease: Confirmation by Polymerase Chain Reaction and Serological Tests, and Successful Treatment with Voriconazole (2003) (13)
Diagnosis of infections with Shiga-like toxin-producing Escherichia coli by use of enzyme-linked immunosorbent assays for Shiga-like toxins on cultured stool samples. (1994) (13)
SHOULD TRAVELLERS TO ASIA BE VACCINATED AGAINST JAPANESE ENCEPHALITIS? (1987) (13)
Serious fungal infections in Korea (2017) (13)
In vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various candida spp (1996) (13)
Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis (2021) (13)
Invasive aspergillosis in a patient with MELAS syndrome (2000) (12)
Acute Aspergillus pneumonia associated with mouldy tree bark-chippings, complicated by anti-glomerular basement membrane disease causing permanent renal failure☆ (2013) (12)
Hyperbaric oxygen therapy in a woman who declined colostomy (1996) (12)
Estimated Burden of Serious Fungal Diseases in Serbia (2018) (12)
Pulmonary TB and chronic pulmonary aspergillosis: clinical differences and similarities. (2021) (12)
Clinical outcomes of patients with chronic pulmonary aspergillosis managed surgically. (2020) (12)
A prospective longitudinal study of chronic pulmonary aspergillosis in pulmonary tuberculosis in Indonesia (APICAL) (2021) (12)
Fungal infections: a survey of laboratory services for diagnosis and treatment. (1996) (12)
Estimated Burden of Serious Fungal Infections in Jamaica by Literature Review and Modelling. (2015) (12)
The treatment of oropharyngeal candidiasis in HIV-infected patients with oral amphotericin B suspension. (1998) (12)
Discrepancies associated with the measurement of itraconazole serum concentrations by bioassays. (1999) (12)
Non-infectious status indicated by detectable IgG antibody to SARS-CoV-2 (2020) (11)
Diagnostic Aspects of Chronic Pulmonary Aspergillosis: Present and New Directions (2019) (11)
Evaluation and comparison of automated and manual ELISA for diagnosis of chronic pulmonary aspergillosis (CPA) in Indonesia. (2020) (11)
Eradication of low-level methicillin-resistant Staphylococcus aureus skin colonization with topical mupirocin. (1988) (11)
Diagnosing pulmonary aspergillosis is much easier than it used to be: a new diagnostic landscape. (2021) (11)
Comparison of three methods for in vitro susceptibility testing of Candida species with flucytosine. (2003) (11)
Estimated burden of fungal infections in Italy. (2018) (11)
Antifungal drug susceptibility testing. Working Party of the British Society for Antimicrobial chemotherapy. (1995) (11)
Characterisation of Aspergillus fumigatus Endocytic Trafficking within Airway Epithelial Cells Using High-Resolution Automated Quantitative Confocal Microscopy (2021) (11)
Editorial commentary: Prophylactic echinocandin: is there a subgroup of intensive care unit patients who benefit? (2014) (11)
Polar lipids of Aspergillus fumigatus, A. niger, A. nidulans, A. flavus and A. terreus. (1998) (11)
Micafungin may be safely administered as outpatient parenteral antimicrobial therapy for chronic pulmonary aspergillosis (2018) (11)
Therapeutic drug monitoring and adverse events of delayed-release posaconazole tablets in patients with chronic pulmonary aspergillosis (2018) (10)
Histoplasmosis in Children; HIV/AIDS Not a Major Driver (2021) (10)
Risk factors for relapse of chronic pulmonary aspergillosis after discontinuation of antifungal therapy (2020) (10)
A dose comparison study of a new triazole antifungal (D0870) in HIV‐positive patients with oral candidiasis (1997) (10)
Aspergillus keratitis following corneal foreign body (2004) (10)
An Estimate of the Burden of Fungal Disease in Norway (2018) (10)
Serious fungal diseases in the Republic of Uzbekistan (2017) (10)
Mixed mould species in laboratory cultures of respiratory specimens: how should they be reported, and what are the indications for susceptibility testing? (2011) (10)
Interferon gamma replacement as salvage therapy in chronic pulmonary aspergillosis: effects on frequency of acute exacerbation and all-cause hospital admission (2020) (10)
Evaluation of knowledge and awareness of invasive fungal infections amongst resident doctors in Nigeria (2020) (10)
Aspergillus fumigatus allergen expression is coordinately regulated in response to hydrogen peroxide and cyclic AMP (2010) (10)
Serious fungal infections in Ecuador (2017) (10)
Histoplasmosis in the Republic of Congo dominated by African histoplasmosis, Histoplasma capsulatum var. duboisii (2021) (10)
Detrimental effect of propylene glycol on natural killer cell and neutrophil function (1987) (10)
The antiseptic Miramistin: a review of its comparative in vitro and clinical activity. (2020) (10)
In vitro and in vivo efficacy of miramistin against drug-resistant fungi. (2019) (10)
Assessment of posaconazole salvage therapy in chronic pulmonary aspergillosis using predefined response criteria. (2018) (10)
Impact of the COVID-19 pandemic on HIV care in Guatemala (2021) (10)
Activity of pradimicin BMS-181184 against Aspergillus spp. (1999) (10)
Antifungal resistance: more research needed (2014) (10)
Determining the burden of fungal infections in Zimbabwe (2021) (10)
Ending deaths from HIV-related cryptococcal meningitis by 2030. (2020) (10)
National trends in incidence, prevalence and disability-adjusted life years of invasive aspergillosis in Iran: a systematic review and meta-analysis (2019) (9)
Itraconazole associated quadriparesis and edema: a case report (2011) (9)
Cryptococcal and Histoplasma Antigen Screening Among People With Human Immunodeficiency Virus in Ghana and Comparative Analysis of OIDx Histoplasma Lateral Flow Assay and IMMY Histoplasma Enzyme Immunoassay (2022) (9)
Estimated burden of fungal infections in Sweden (2019) (9)
Immunoassay of Aflatoxin in Food and Human Tissue (1989) (9)
Cure of chronic invasive sinus aspergillosis with oral saperconazole. (1995) (9)
Sub-cutaneous phaeohyphomycosis caused by Cladophialophora devriesii in a United Kingdom resident. (2006) (9)
Pulmonary Aspergillosis in Patients with Suspected Ventilator-associated Pneumonia in UK Intensive Care Units. (2020) (9)
Pulmonary and Extrapulmonary Manifestations of Fungal Infections Misdiagnosed as Tuberculosis: The Need for Prompt Diagnosis and Management (2022) (9)
Treatment of HIV‐related fluconazole‐resistant oral candidosis with D0870, a new triazole antifungal (1998) (9)
Chronic Pulmonary Aspergillosis Situation among Post Tuberculosis Patients in Vietnam: An Observational Study (2021) (9)
Termination of development of D0870. (2001) (9)
Prevalence of Histoplasmosis among Persons with Advanced HIV Disease, Nigeria (2022) (8)
Assessment of therapeutic response of oropharyngeal and esophageal candidiasis in AIDS with use of a new clinical scoring system: studies with D0870. (1999) (8)
F508del CFTR gene mutation in patients with allergic bronchopulmonary aspergillosis (2018) (8)
Does One Voriconazole Breakpoint Suit All Candida Species? (2007) (8)
Posaconazole responsive cerebral aspergillosis in an immunocompetent adult (2014) (8)
An evaluation of nebulised amphotericin B deoxycholate (Fungizone®) for treatment of pulmonary aspergillosis in the UK National Aspergillosis Centre (2019) (8)
Estimating the Burden of Serious Fungal Infections in Uruguay (2018) (8)
A public resource for metabolic pathway mapping of Aspergillus fumigatus Af293. (2011) (8)
Aspergillus nodules in chronic granulomatous disease attributable to Aspergillus ochraceus (2017) (8)
An Estimate of Severe and Chronic Fungal Diseases in the Republic of Kazakhstan (2018) (8)
Antifungal drug resistance: an update (2022) (8)
Skin prick reactivity among asthmatics in East Africa (2020) (8)
Invasive pulmonary aspergillosis diagnosed by blood culture and successfully treated. (1987) (8)
Identifying rare diseases using electronic medical records: the example of allergic bronchopulmonary aspergillosis (2017) (8)
Nebulised N-Acetylcysteine for Unresponsive Bronchial Obstruction in Allergic Brochopulmonary Aspergillosis: A Case Series and Review of the Literature (2018) (8)
Candida glabrata Oesophagitis in a Patient Without HIV Infection (2000) (7)
Screening for acute disseminated histoplasmosis in HIV disease using urinary antigen detection enzyme immunoassay: A pilot study in Cameroon. (2021) (7)
FLUORESCENCE ANALYSIS OF REACTIVE OXYGEN SPECIES (ROS) GENERATED BY SIX ISOLATES OF ASPERGILLUS FUMIGATUS (2001) (7)
Subacute Invasive Aspergillosis Associated With Sorafenib Therapy for Hepatocellular Carcinoma. (2018) (7)
Estimates of serious fungal infection burden in Côte d'Ivoire and country health profile. (2020) (7)
Anti-Cryptococcus neoformans antibodies during cryptococcosis in patients with the acquired immunodeficiency syndrome (1995) (7)
Aspergillus niger infection in an immunosuppressed patient confined solely to the brain (2017) (7)
Inference of Aspergillus fumigatus pathways by computational genome analysis: Tricarboxylic acid cycle (TCA) and glyoxylate shunt (2004) (7)
Lung microbiome is associated with asthma severity in fungal associated asthma (2015) (7)
Effect of patient immunodeficiencies on the diagnostic performance of serological assays to detect Aspergillus-specific antibodies in chronic pulmonary aspergillosis (2021) (7)
Executive Summary of the 2017 ESCMID -ECMM Guideline for the Diagnosis and Management of Aspergillus Disease (2018) (7)
The collection of Cheumatopsyche analis in Hawaii (1967) (7)
Current burden of serious fungal infections in Republic of Congo (2020) (7)
Serious fungal disease incidence and prevalence in Indonesia (2021) (7)
Incidence of Histoplasmosis in a Cohort of People with HIV: From Estimations to Reality (2021) (6)
Burden of Serious Fungal Infection in Nigeria Les Fardeaux D ’ une Infection Mycosique Grave au Nigeria (2014) (6)
Audit of laboratory mycology services for the management of patients with fungal infections in the northwest of England (2006) (6)
Invasive pulmonary aspergillosis with spontaneous resolution and the diagnostic utility of PCR from tissue specimens. (2004) (6)
Deciphering Aspergillus fumigatus cyp51A-mediated triazole resistance by pyrosequencing of respiratory specimens (2020) (6)
Detection of Pneumocystis jirovecii by quantitative real-time PCR in oral rinses from Pneumocystis pneumonia asymptomatic human immunodeficiency virus patients. (2019) (6)
Intravenous therapy for chronic pulmonary aspergillosis: A systematic review and meta‐analysis (2020) (6)
The role of medical mycology societies in combating invasive fungal infections in low‐ and middle‐income countries: A Nigerian model (2018) (6)
Comment on: Antifungal therapy: drug-drug interactions at your fingertips. (2016) (6)
Tackling cryptococcal meningitis in Nigeria, one-step at a time; the impact of training (2020) (6)
A comparative view of the genome of Aspergillus fumigatus. (2007) (6)
Prevalence of phthioic acid in Aspergillus species. (1997) (6)
Cost implications of alternative treatments for AIDS patients with cryptococcal meningitis. (1992) (6)
Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. (2006) (6)
Mycobacterium chelonae finger infection associated with Raynaud’s phenomenon (2004) (6)
Performance of LDBio Aspergillus WB and ICT Antibody Detection in Chronic Pulmonary Aspergillosis (2021) (6)
Successful long-term terbinafine therapy in an asthmatic patient with Aspergillus sensitization and bronchiectasis (2017) (5)
European confederation of medical mycology expert consult—An ECMM excellence center initiative (2020) (5)
Transient nephrogenic diabetes insipidus following high-dose cyclophosphamide chemotherapy and autologous bone marrow transplantation. (1987) (5)
Optimising the cut-off of the Bordier Aspergillus IgG ELISA for the diagnosis of chronic pulmonary aspergillosis. (2020) (5)
Sarcoidosis and aspergillosis: a tough combination (2017) (5)
A blood isolate of Neisseria meningitidis showing reduced susceptibility to quinolones in Hong Kong (2007) (5)
Chronic pulmonary aspergillosis in patients with active pulmonary tuberculosis with persisting symptoms in Uganda (2022) (5)
Pilot study of a new triazole derivative (D0870) in HIV patients with oral candidiasis (1994) (5)
P1951 Dose response in neutropenic mice with disseminated infec-tion of multiple strains of Aspergillus fumigatus with widely varying MIC and MFC values treated with isavuconazole (2007) (5)
New estimation of the prevalence of chronic pulmonary aspergillosis (CPA) related to pulmonary TB – a revised burden for India (2022) (5)
Time to finish with "AIDS"? (1992) (5)
Comparative analysis of an emerging fungal pathogen , Aspergillus terreus (2004) (5)
A case of spotted fever group rickettsiosis imported into the United Kingdom and treated with ciprofloxacin: a case report (2008) (5)
Cutaneous childhood sarcoidosis--a rare disease refractory to treatment. (2003) (5)
Single-spore cultures of the sequences strain of Aspergillus fumigatus (Af293) have significantly different mortality rates in a murine model of IPA (2006) (5)
In-vitro activity of D0870, a new triazole antifungal drug, in comparison with fluconazole and itraconazole against Aspergillus fumigatus and Candida krusei. (1997) (5)
COMPUTED TOMOGRAPHY OF CHEST IN DIAGNOSIS OF MILIARY TUBERCULOSIS (1987) (5)
From culturomics to metagenomics: the mycobiome in chronic respiratory diseases (2019) (5)
Evolving Etiology of Fungal Infection in the 1990s (1994) (5)
The burden of serious fungal infections in Sierra Leone: a national estimate (2021) (5)
Skin rash after triple vaccine. (1987) (5)
Optimising antifungal therapy for individual patients (2004) (5)
Long-Term Stability at -20 degrees C of Aspergillus Galactomannan in Serum and Bronchoalveolar Lavage Specimens (4)
Pulmonary infection in the immunocompromised host. (1990) (4)
In Vitro Activity of the Echinocandin HMR3270 against Aspergillus spp. (2001) (4)
Invasive pulmonary aspergillosis 10 years post bone marrow transplantation: a case report (2009) (4)
Linking calcium signaling and mitochondrial function in fungal drug resistance (2020) (4)
The WHO fungal priority pathogens list as a game-changer (2023) (4)
Oral and cutaneous features of acute human immunodeficiency virus infection. (1987) (4)
189 – Opportunistic and Systemic Fungi (2017) (4)
Burden of fungal infections in Algeria (2017) (4)
Induced expression of a novel Aspergillus fumigatus putative drug efflux gene in response to itraconazole (1999) (4)
Diagnostic capacity for invasive fungal infections in advanced HIV disease in Africa: a continent-wide survey. (2022) (4)
Acute kidney injury: an unusual complication of posaconazole use (2018) (4)
Opportunistic fungal infections in persons living with advanced HIV disease in Lagos, Nigeria; a 12-year retrospective study (2020) (4)
Defective interferon-gamma production is common in chronic pulmonary aspergillosis. (2021) (4)
The Burden of Serious Fungal Infections in Tajikistan (2019) (4)
Serious fungal diseases in Democratic Republic of Congo – Incidence and prevalence estimates (2021) (4)
Fungal Diseases in Taiwan—National Insurance Data and Estimation (2019) (4)
Eradication of Low-Level Methicillin-Resistant Staphylococcus aureus Skin Colonization with Topical Mupirocin (1988) (4)
Correction for Macdonald et al., “Inducible Cell Fusion Permits Use of Competitive Fitness Profiling in the Human Pathogenic Fungus Aspergillus fumigatus” (2019) (4)
Analysis of human sera for aflatoxin. (1993) (3)
P183 Global burden of allergic bronchopulmonary aspergillosis (ABPA) complicating asthma (2010) (3)
Evaluation of an Aspergillus IgG/IgM lateral flow assay for serodiagnosis of fungal asthma in Uganda (2021) (3)
Vitamin D deficiency in asthma patients with allergic bronchopulmonary aspergillosis (ABPA) (2013) (3)
Reply to “Insufficient Demonstration of Long-Term Stability of Aspergillus Galactomannan” (2014) (3)
Integration of fungal diseases into health systems in Latin America. (2020) (3)
Human Fungal Infections in Kuwait—Burden and Diagnostic Gaps (2020) (3)
Muco-cutaneous retinoid-effects and photosensitivity related to the novel triazole antifungal agent voriconazole (2001) (3)
Chronic pulmonary aspergillosis following pulmonary embolism (2018) (3)
In vitro susceptibility of non-Aspergillus allergenic fungal species to azoles. (2009) (3)
The treatment of invasive aspergillosis (1991) (3)
Emerging Problems in Infectious Diseases Estimated burden of fungal infections in Kenya (2016) (3)
Reply to Verweij et al (2007) (3)
Unravelling the Molecular Identification and Antifungal Susceptibility Profiles of Aspergillus spp. Isolated from Chronic Pulmonary Aspergillosis Patients in Jakarta, Indonesia: The Emergence of Cryptic Species (2022) (3)
The estimated burden of fungal diseases in South Africa (2019) (3)
Efficacy of LD Bio Aspergillus ICT Lateral Flow Assay for Serodiagnosis of Chronic Pulmonary Aspergillosis (2022) (3)
The Burden of Serious Fungal Infections in Kyrgyzstan (2019) (3)
Comment on: Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model. (2015) (3)
Use of the 6-methylsalicylic-acid-synthase gene as a discriminating marker betweenaspergillus terreus andAspergillus flavipes (2008) (3)
Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement (2022) (3)
Idiopathic oedema and diuretics. (1987) (3)
Is fungal disease in Sri Lanka underestimated? A comparison of reported fungal infections with estimated disease burden using global data (2015) (3)
The application of serum mannitol determinations for the diagnosis of invasive pulmonary aspergillosis in bone marrow transplant patients (1994) (3)
Correlation of in vitro MIC and MFC against isavuconazole, voriconazole, and amphotericin B of Aspergillus with in vivo outcome in mice with disseminated Aspergillosis (2008) (3)
Restriction Endonuclease Analysis ofHumanandBovine GroupB Streptococci forEpidemiologic Study (1989) (3)
Fungal diseases in Taiwan – National Insurance Data and Estimation (2019) (3)
KAWASAKI DISEASE AND ASPIRIN (1983) (3)
Burden of serious fungal infections in Germany (2014) (2)
Estimated burden of serious fungal infections in Togo (2021) (2)
The challenge of access to refined fungal diagnosis: An investment case for low- and middle-income countries. (2021) (2)
RIEF OBSERVATION oriconazole Treatment for Subacute Invasive and Chronic ulmonary Aspergillosis (2006) (2)
Fungal infections in transplant recipients: pros and cons of immunosuppressive and antimicrobial treatment. (2021) (2)
Impact of high baseline Aspergillus-specific IgG levels on weight and quality-of-life outcomes of patients with chronic pulmonary aspergillosis. (2020) (2)
Treatment of Fluconazole resistant oral candidosis with D0870 in patients with AIDS (1994) (2)
WHOLE BLOOD EXCHANGE AS TREATMENT FOR LEGIONELLOSIS (1987) (2)
Failure of single dose amoxycillin as prophylaxis against endocarditis. (1984) (2)
Chronic pulmonary aspergillosis is common among patients with presumed tuberculosis relapse in Ghana (2022) (2)
Estimating the burden of serious fungal diseases in Canada (2015) (2)
Estimated Incidence and Prevalence of Serious Fungal Infections in Morocco (2022) (2)
Agility and Sustainability: A Qualitative Evaluation of COVID-19 Non-pharmaceutical Interventions in the UK Logistics Sector (2022) (2)
BronchUK: protocol for an observational cohort study and biobank in bronchiectasis (2021) (2)
FURTHER PROBLEMS WITH THEOPHYLLINE (1984) (2)
Gastroesophageal Reflux Disease and Pulmonary Diseases Associated with Aspergillosis: Is There a Connection? (2017) (2)
Fungal asthma among Ugandan adult asthmatics. (2021) (2)
Candida inconspicua, another Fluconazole resistant candida species in HIV patients (1995) (2)
Interrogation of related clinical pan-azole resistant Aspergillus fumigatus strains – G138C, Y431C and G434C SNPs in cyp51A, Upregulation of cyp51A and integration and activation of transposon Atf1 into cyp51A promoter. (2011) (2)
Drug–drug interaction database for safe prescribing of systemic antifungal agents (2021) (2)
Estimation of the burden of chronic and allergic aspergillosis in India (2013) (2)
Too Many Mouldy Joints - Marijuana (2011) (2)
The burden of serious fungal infections in Azerbaijan (2021) (2)
Neurospora sitophila pulmonary infection in a patient with AIDS. (1997) (2)
IDENTIFICATION, ISOLATION, CLONING AND SEQUENCING APARTIALANNEXIN GENE FROM AUREOBASIDIUM PULLULANS (2005) (2)
Quantifying Deaths from Aspergillosis in HIV Positive People (2022) (2)
Advances in invasive fungal infection and antifungal therapy: Introduction. (2001) (2)
Attainment of therapeutic posaconazole serum levels during coadministration with rifampicin. (2020) (2)
Clinical features of peritoneal tuberculosis. (1989) (2)
Is an azole-resistant Aspergillus hotspot emerging in South-East Asia? (2021) (2)
Clinical Performance of FXGTM : RESP (Asp +) assay for Pneumocystis jirovecii on respiratory specimens (2008) (1)
Sequencing of mitochondrial genomes of nine Aspergillus and Penicillium species identifies mobile introns and accessory genes as main sources of genome size variability (2012) (1)
Impact of Changes of the 2020 Consensus Definitions of Invasive Aspergillosis on Clinical Trial Design: Unintended Consequences for Prevention Trials? (2021) (1)
Prophylaxis and Treatment of Invasive Aspergillosis: Who and How of Prophylaxis, Treatment, and New Therapies (2020) (1)
Updated estimated incidence and prevalence of serious fungal infections in Trinidad and Tobago (2021) (1)
EMPIRICAL THERAPY OF FUNGAL INFECTIONS IN NEUTROPENIC PATIENTS (1998) (1)
M27 Bronchiectasis multicentre cohort; baseline demographics from BRONCHUK (2019) (1)
The incidence of cutaneous squamous cell carcinoma in patients receiving voriconazole therapy for chronic pulmonary aspergillosis (2020) (1)
Correction: Mitochondrial Complex I Is a Global Regulator of Secondary Metabolism, Virulence and Azole Sensitivity in Fungi (2017) (1)
Prevalence of Aspergillus fumigatus skin positivity in adults without an apparent/known atopic disease in Uganda (2021) (1)
Burden of Serious Fungal Infections in India (2022) (1)
Patients with suspected Lassa fever in London during 1984 (1986) (1)
Prevalence of possible severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA) in a UK secondary care hospital (2013) (1)
Standardization of Aspergillus IgG diagnostic cutoff in Nigerians (2021) (1)
Histoplasmosis in Africa: Current perspectives, knowledge gaps, and research priorities (2022) (1)
The burden of serious fungal infections in Ghana (2019) (1)
Prospective Evaluation of Positivity Rates of Aspergillus-Specific IgG and Quality of Life in HIV-Negative Tuberculosis Patients in Lagos, Nigeria (2022) (1)
Invasive Aspergillosis in Cancer Patients (2017) (1)
Estimated Burden of Fungal Infections in Oman (2020) (1)
Clinical Performance of FXGTM: RESP (Asp +) assay for Aspergillus on respiratory specimens (2008) (1)
Early management of community-acquired asthma (1994) (1)
The Case for Fungal Keratitis to Be Accepted as a Neglected Tropical Disease (2022) (1)
P1950 In vivo efficacy of the triazole BAL8557 against disseminated Candida albicans in mice assessed by survival and tissue bur-den in temporarily and persistently neutropenic mice treated with 1-7 doses of drug over a dose range of 20-80\% of Emax (2007) (1)
A comparison of the precipitation technique and ImmunoCAP® FIEA for measurement of IgG antibodies to Aspergillus (2010) (1)
The Impact of Corticosteroids on the Outcome of Fungal Disease: a Systematic Review and Meta-analysis (2023) (1)
S19 Real time PCR in the identification and management of Aspergillus in CF (2010) (1)
Comment on: “Global Consumption Trend of Antifungal Agents in Humans from 2008 to 2018: Data from 65 Middle‐ and High‐Income Countries” (2022) (1)
Invasive Aspergillosis after Renal Transplantation (2023) (1)
Triazole resistance in Aspergillus fumigatus isolates in Africa: a systematic review. (2022) (1)
In vitro activity of saperconazole (R66 905) compared with amphotericin B and itraconazole againstAspergillus species (1990) (1)
Diagnosis of chronic pulmonary aspergillosis (CPA) complicating pulmonary tuberculosis by chest X-ray (2018) (1)
Assessment of Posaconazole Salvage Therapy in Chronic Pulmonary Aspergillosis by Using Predefined Response Criteria (2018) (1)
Medicine: A Core Text with Self-Assessment (1997) (1)
Allergic diseases and fungal exposome: Prevention is better than cure (2022) (1)
Evaluation of multiple open-source deep learning models for detecting and grading COVID-19 on chest radiographs (2021) (1)
IDSA guidelines for aspergillosis (2008) (1)
Invasive Aspergillosis in a patient with Asthma post H1N1 PneumoniaD Nayar1, Cook P1, Lim L1, Allison D1, Denning D2County Durham and Darlington Foundation Trust1National Aspergillosis Centre, University Hospital of South Manchester2: Category: Clinical lesson (2011) (1)
Are platelet volume indices of clinical use in COVID-19? A systematic review (2022) (1)
Pulmonary nodules due to reactive systemic amyloidosis ( AA ) in Crohn ' s disease (1)
P20 Fatigue and Poor Lung Function Are Significantly Associated with Impaired Health-Related Quality of Life (HRQoL) in a Large Cohort of Patients with Chronic Pulmonary Aspergillosis (2012) (0)
IL-17A in severe asthma, severe asthma with fungal sensitisation and ABPA (2015) (0)
MOLECULAR DETECTION OF PHOSPHOLIPASE B AS AN EFFECTIVE FACTOR IN VIRULENCE OF MICRORGANISIMS (2004) (0)
The incidence of cutaneous squamous cell carcinoma in patients receiving voriconazole therapy for chronic pulmonary aspergillosis (2020) (0)
Microaerophilic MICs and MFCs of Amphotericin B and Itraconazole with Aspergillus spp. Compared with air. (2002) (0)
Suppression of the hypothalamus-pituitary-adrenal axis in asthmatics on inhaled steroids treated with itraconazole (2008) (0)
ctivity of aminocandin (IP960; HMR3270) compared with amphotericin B, traconazole, caspofungin and micafungin in neutropenic murine models of isseminated infection caused by itraconazole-susceptible and -resistant strains f Aspergillus fumigatus (2009) (0)
Burden of Serious Fungal Diseases in Romania (2018) (0)
Comparative performance of galactomannan and Aspergillus PCR in sputum from patients with ABPA and CPA (2016) (0)
Serious fungal infections in Canada (2017) (0)
Molecular Detection of Phospholipase B3 as an Effective Factor in Virulence of Aspergillus Fumigatus (2011) (0)
When to use fluconazole (1995) (0)
Burden of serious fungal infections in Honduras (2022) (0)
Serodiagnosis in the management of aspergillosis. (2014) (0)
Halo Sign and Improved Outcome. Authors' reply (2007) (0)
Flucytosine and its clinical usage (2023) (0)
Burden of serious fungal infections in Guatemala (2017) (0)
IDENTIFICATION OF PHOSPHOLIPASE D GENE AS A CONTRIBUTING FACTOR IN GROWTH AND VIRULENCE OF MICROORGANISMS (2007) (0)
Updated estimation of the burden of fungal disease in Vietnam (2022) (0)
Corticosteroids in pneumococcal meningitis. (1997) (0)
IgE expression in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA) (2013) (0)
A.fumigatusand the bronchial epithelium - A permissive relationship? (2016) (0)
Bacterial infections: Yersinia (1987) (0)
Modelling the impact of non-pharmaceutical interventions on workplace transmission of SARS-CoV-2 in the home-delivery sector (2022) (0)
Reviewer's reply (1996) (0)
Fungal naildisease: aguide togood practice(report ofaWorking GroupoftheBritish Society forMedical Mycology) (1995) (0)
Definition of Chronic Pulmonary Aspergillosis in Resource-Constrained Settings (2019) (0)
The Global Impact of Mold Infections (2017) (0)
Environmental Moulds and Human Disease: Is There a Connection? (2008) (0)
ARREST OF A DRUG DEALER IN HOSPITAL (1985) (0)
A Cross-Sectional Survey to Measure the Prevalence of Chronic Pulmonary Aspergillosis (CPA) Complicating Pulmonary Tuberculosis in Northern Uganda (2017) (0)
The design, development and running of a website for medical education: The Aspergillus website as an example (1999) (0)
Contents, Vol. 38, Supplement 1, 1992 (1992) (0)
Contents, Vol. 38, Supplement 1, 1992 (1992) (0)
Importance of Aspergillus-Specific Antibody Screening for Diagnosis of Chronic Pulmonary Aspergillosis after Tuberculosis Treatment: A Prospective Follow-Up Study in Ghana (2022) (0)
Diagnostic Mycology Laboratories Should Have a Central Role for the Management of Fungal Disease (2022) (0)
Serious fungal infections in Egypt (2017) (0)
Diversity of Candida spp in adult CF patients (2009) (0)
Fungus (mould) allergic pulmonary disease (2008) (0)
Fungal respiratory infections Hayes and Denning Prevalence of asthma and allergic bronchopulmonary aspergillosis in adults (2013) (0)
Erratum to “Online Learning Resources Enhanced Teaching and Learning of Medical Mycology among Medical Students in Gulu University, Uganda” (2020) (0)
Performance ofCryptococcus Antigen LatexAgglutination Kitson SerumandCerebrospinal Fluid Specimens ofAIDSPatients before andafter Pronase Treatment (1991) (0)
Pocket Reference to Opportunistic Fungal Infections (1994) (0)
P1867 Detection of fungi in hospital water supplies using molecular beacons (2007) (0)
Early management of community-acquired pneumonia [correction of asthma]. (1994) (0)
Estimated burden of serious fungal infections in Ethiopia (2019) (0)
P388 High rate of chronic pulmonary aspergillosis in active TB patients in Indonesia with GeneXpert positive (2022) (0)
Current situation of fungal diseases in Eritrea (2022) (0)
Advances against aspergillosis (September 9–11, 2004, San Francisco, California) (2005) (0)
Novel therapeutic options for invasive fungal infections (2021) (0)
Changing Character is t ics of Invas ive Pulmonary Aspergi l los i s on Sequent ia l Thorac ic Computed Tomography Scans in Pat ients With Neutropenia (2000) (0)
Diagnosing disseminated histoplasmosis in advanced HIV/AIDS disease in Cameroon using a point of care lateral flow assay (2022) (0)
Efficacy and safety of nebulised amphotericin in severe asthma with fungal sensitisation. (2013) (0)
P286 Histoplasmosis in Sri Lanka (2022) (0)
P482 Burden of serious fungal infections in India (2022) (0)
Pneumococcal 13-valent polysaccharide vaccination (PCV13) response in patients with pulmonary aspergillosis (2020) (0)
ARTICLES AND COMMENTARIES (2011) (0)
Essential in vitro diagnostics for advanced HIV and serious fungal diseases: international experts’ consensus recommendations (2019) (0)
IDENTIFICATION, ISOLATION, CLONING AND SEQUENCING OF FLUCONAZOLE RESISTANCE GENE IN ASPERGILLUS FUMIGATUS (2008) (0)
Trends in the Management of Systemic Fungal Infections: Meeting, Nijmegen, September 1991: Selected Papers (1992) (0)
Bacterial infections: the Campylobacters–pyloridis and jejuni (1987) (0)
Reply to Troke and Hitchcock's letter (1994) (0)
Fungal Diseases in People with HIV/AIDS: Focus on New Developments (2009) (0)
Adverse drug reactions to the new triazole, voriconazole — the need for therapeutic drug monitoring (2002) (0)
Diagnostic options for pulmonary fungal diseases in Africa (2023) (0)
Antifungal prophylaxis in neutropenia - is it worth it? (1999) (0)
Aspergillosis and Other Molds (2009) (0)
Improving awareness, diagnosis and management of invasive fungal infections in Ghana: establishment of the Ghana Medical Mycology Society (2022) (0)
P161 Global prevalence of chronic pulmonary aspergillosis (CPA) following pulmonary tuberculosis (PTB) (2010) (0)
The assessment of therapeutic response of oropharyngeal and oesophageal candidiasis in AIDS using a new scoring system: studies with D0870. (1999) (0)
Real time PCR to aid the identification and management of Aspergillus in CF (2010) (0)
141 Aspergillus fumigatus degrades the respiratory mucins MUC5B and MUC5AC (2017) (0)
EXCEPTION IN GENES START CODON (2008) (0)
Gastroesophageal Reflux Disease and Pulmonary Diseases Associated with Aspergillosis: Is There a Connection? (2017) (0)
Fungal Disease in cystic fibrosis and chronic respiratory disorders (2017) (0)
Emerging respiratory tract infections 5 Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options (2014) (0)
Prevalence of chronic pulmonary aspergillosis in patients with tuberculosis from Iran (2015) (0)
REVIEW ARTICLE Antifungal Drug Resistance in Aspergillus (2000) (0)
Coccidioides, Infection and Immunity (1998) (0)
Fungal allergy in adult cystic fibrosis (2009) (0)
ITRACONAZOLE TREATMENT OF ASPERGILLOSIS / DENNING ET AL 0 ’ MIC MFC (2004) (0)
Fungal infections in Algeria. (2023) (0)
COLOURING AGENTS IN MEDICINE FOR ASTHMATIC CHILDREN (1985) (0)
Serious fungal infections in Chile (2017) (0)
Review Endemic mycoses: a treatment update (1999) (0)
Fungal infection in the compromised patient (1991) (0)
Gastrointestinal Histoplasmosis: A Descriptive Review, 2001–2021 (2023) (0)
An estimate of the burden of serious fungal diseases in Greece (2016) (0)
Supplementary material from "Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500 000 by 2020 to be realized" (2016) (0)
[Itraconazole in systemic fungal infections]. (1991) (0)
Partial 16S rDNA analysis of oral Treponema (1997) (0)
Cavitary Pulmonary Lesion In Allergic Bronchopulmonary Aspergillosis Successfully Treated With Posaconazole (2012) (0)
Respiratory Function in Ex-Preterm Subjects. Authors' reply (2009) (0)
IgE expression in severe asthma with fungal sensitisation (SAFS) and ABPA (2013) (0)
Prophylactic fluconazole and marrow transplantation. (1992) (0)
Lung colonization by Aspergillus fumigatus is controlled by ZNF77 (2018) (0)
A Review of Onychomycosis Due to Aspergillus Species (2017) (0)
Improvement in asthma severity and control by voriconazole and posaconazole in severe asthma with fungal sensitization (SAFS) and ABPA (2012) (0)
ANALYSIS OF A EUKARIOTIC GENE (2005) (0)
Calling upon all public health mycologists (2017) (0)
Letters to the Editor Multidrug-Resistant Trichosporon asahii Isolates Are Susceptible to Voriconazole (2003) (0)
Acute meningo‐encephalitis in pregnancy—a problem of differential diagnosis (1996) (0)
Role of Real time PCR and Galactomannan in the classification of Aspergillus disease in CF (2012) (0)
Antibodies against Histoplasma capsulatum and Aspergillus fumigatus among chronic TB patients in Indonesia: a cross-sectional study. (2023) (0)
WITHDRAWN: New Drug Therapies -Voriconazole (2006) (0)
Aspergillus Fumigatus Pneumonia in a Hellenic Shepherd dog (2011) (0)
A systematic review and meta-analysis: The impact of corticosteroids onthe outcome of fungal disease (2022) (0)
The Infectious Diseases Manual (1996) (0)
Minimal inhibitory concentration distributions and epidemiological cut-offs of amphotericin B, flucytosine, fluconazole, itraconazole and voriconazole for Candida spp. using the EUCAST methodology for susceptibility testing (2008) (0)
Serious fungal infections in Portugal (2017) (0)
The clinical spectrum of aspergillosis in chronic obstructive pulmonary disease (2023) (0)
A 27-year-old woman with acute, severe asthma who developed respiratory failure. (2010) (0)
THORAXJNL155515 638..640 (0)
P143 Incidence of chronic pulmonary aspergillosis in a cohort of bacteriologically confirmed TB patients at a tertiary hospital in Ghana (2022) (0)
Serious fungal diseases in the Republic of Uzbekistan (2017) (0)
Management of advanced HIV disease in Africa. (2023) (0)
The estimated burden of fungal diseases in Mali. (2022) (0)
Re-drawing the Maps for Endemic Mycoses (2020) (0)
Book Review Transplant Infections Second edition. Edited by Raleigh A. Bowden, Per Ljungman, and Carlos V. Paya. 730 pp., illustrated. Philadelphia, Lippincott Williams & Wilkins, 2003. $179. 0-7817-3907-1 (2004) (0)
Serious fungal infections in Pakistan (2017) (0)
Correlation of MICs of ketoconazole (KTZ) and itraconazole (ITZ) for C. albicans with clinical outcome of treatment of oropharyngeal candidiasis in HIV patients with a population pharmacokinetic analysis (1998) (0)
Comprar Master Medicine: Medicine | Paul A. O'Neill | 9780443103209 | Churchill Livingstone (2007) (0)
Early diagnosis of invasive aspergillosis (2000) (0)
Burden of serious fungal infections in Bangladesh (2017) (0)
Burden of fungal infections in Kenya (2023) (0)
Comparative analysis of three Aspergillus genomes (2007) (0)
Pharmacokinetics and Pharmacodynamics of a Novel Triazole, Isavuconazole: Mathematical Modeling, Importance of Tissue Concentrations, and Impact of Immune Status on Antifungal Effect (cid:1) (2009) (0)
Standards of care for invasive fungal infections – Authors' reply (2003) (0)
THEOPHYLLINE DOSES (1984) (0)
The incidence of Histoplasmosis and Cryptococcal antigenemia among patients attending a Large HIV Clinic in Trinidad (2023) (0)
Serious fungal infections in Peru (2017) (0)
Detection of Aspergillus antibodies by a new indirect haemagglutination assay (2014) (0)
Viewing annotated aspergillus genomes on the central aspergillus data repository (CADRE) website. (2005) (0)
In vitro activity of saperconazole (R66 905) compared with amphotericin B and itraconazole againstAspergillus species (2005) (0)
The effect of proteinase inhibitors (PI) on the incidence of oropharyngeal candidiasis (OPC) in an HIV cohort (1998) (0)
Role of real time PCR and specific IgG in identifying patients with Aspergillus colonisation (2010) (0)
Update on Moulds, Asthma and Fungal Sinusitis (2008) (0)
The Performance of Real-Time PCR, Galactomannan, and Fungal Culture in the Diagnosis of Invasive Aspergillosis in Ventilated Patients with Chronic Obstructive Pulmonary Disease (COPD) (2012) (0)
Systemic and opportunistic fungi (2017) (0)
A multicenter survey of asymptomatic cryptococcal antigenemia among patients with advanced HIV disease in Nigeria (2023) (0)
Chronic Respiratory Diseases Burden and Healthcare Facilities (2022) (0)
Chronic pulmonary aspergillosis may frequently complicate treated tuberculosis (2013) (0)
P111 Exhaled breath biomarkers in pulmonary aspergillosis (2017) (0)
M26 Convergent validity of bronchiectasis quality of life tools in the BRONCH-UK registry (2019) (0)
S92 Nebulised Amphotericin in Allergic bronchopulmonary Aspergillosis (ABPA) and severe asthma with fungal sensitisation (SAFS) (2013) (0)
P108 Reclassification of aspergillosis phenotype in adult CF patients & 10 year follow up data (2018) (0)
Serious fungal infections in the Philippines (2017) (0)
P21 Long Term Antifungal Treatment (LTAFT) is Effectively Associated with Improvement in Health Status (HS) in Patients with Chronic Pulmonary Aspergillosis (CPA) (2012) (0)
Book Review M.A. Klich, Identification of Common Aspergillus Species, ASM Press, Washington, DC, 2002, 116 pp., $39.95. (2005) (0)

This paper list is powered by the following services:

Other Resources About David Denning

en.wikipedia.org

What Schools Are Affiliated With David Denning?

David Denning is affiliated with the following schools:

David Denning's Academic­Influence.com Rankings